Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma (original) (raw)
Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models
Loreto Boix
Cancers, 2020
View PDFchevron_right
Apoptotic blocks and chemotherapy resistance: strategies to identify Bcl2 protein signatures
Ozgur Gul
Briefings in Functional Genomics and Proteomics, 2008
View PDFchevron_right
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy
Martin Dyer
Cell Death and Differentiation, 2009
View PDFchevron_right
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
Paul Jeng
Nature Communications, 2017
View PDFchevron_right
Unlocking the Therapeutic Potential of BCL-2 Associated Protein Family: Exploring BCL-2 Inhibitors in Cancer Therapy
Yasser Bustanji
Biomolecules & therapeutics, 2024
View PDFchevron_right
BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment
Frank Essmann
Cell Death & Disease
View PDFchevron_right
Down-regulation of apoptosis-related bcl-2 but not bcl-xL or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells
B. Ogretmen
International Journal of Cancer, 1996
View PDFchevron_right
Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma
Robert Preissner
The Journal of biological chemistry, 2017
View PDFchevron_right
Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma
Robert Preissner
Journal of Experimental Medicine, 2010
View PDFchevron_right
BCL-2 Family Inhibitors Enhance Histone Deacetylase Inhibitor and Sorafenib Lethality via Autophagy and Overcome Blockade of the Extrinsic Pathway to Facilitate Killing
Roland Reinehr
Molecular Pharmacology, 2009
View PDFchevron_right
Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma
Susan Peirce
Cancer Research, 2012
View PDFchevron_right
The Stress Protein BAG3 Stabilizes Mcl-1 Protein and Promotes Survival of Cancer Cells and Resistance to Antagonist ABT-737
Mariana Boiani
Journal of Biological Chemistry, 2013
View PDFchevron_right
Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process
Andrea Ferreira-Gonzalez
Blood, 2012
View PDFchevron_right
Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
Marilina García Aranda
International Journal of Molecular Sciences, 2018
View PDFchevron_right
BCL-2 protein family: attractive targets for cancer therapy
deeksha kaloni
Apoptosis
View PDFchevron_right
Protect and serve: Bcl-2 proteins as guardians and rulers of cancer cell survival
Philippe Juin
Cell Cycle, 2013
View PDFchevron_right
Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis
maricela ramirez
Cell death & disease, 2018
View PDFchevron_right
ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein
Guan Wang
Cancer Chemotherapy and Pharmacology, 2011
View PDFchevron_right
Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli
Patricia Sancho, Isabel Fabregat, Conrado Rodriguez
Journal of Cellular Physiology, 2012
View PDFchevron_right
Preclinical Development The Bcl-2 / Bcl-XL / Bcl-w Inhibitor , Navitoclax , Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo
Bernard Liu
2011
View PDFchevron_right
Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation
Maria Shoshan
Carcinogenesis, 2009
View PDFchevron_right
Targeting Bcl-2 Family of Proteins: An Important Strategy in Cancer Therapeutics
RAKESH R SOMANI
View PDFchevron_right
The Bcl-2 family: roles in cell survival and oncogenesis
David Huang
Oncogene, 2003
View PDFchevron_right
Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
Karen Williams
Molecular Cancer Therapeutics, 2013
View PDFchevron_right
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway
Michael Andreeff
Leukemia, 2008
View PDFchevron_right
Proapoptotic BH3-Only BCL-2 Family Protein BIM Connects Death Signaling from Epidermal Growth Factor Receptor Inhibition to the Mitochondrion
Geoffrey Shapiro
Cancer Research, 2007
View PDFchevron_right
Co‐expression of Bcl‐2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization
Aditi Agarwal
Liver, 1999
View PDFchevron_right
Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing by a Novel Small Molecule Inhibitor of Bcl-2
Zaneta Nikolovska-Coleska
Cancer Research, 2004
View PDFchevron_right
Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy
Elena Varin
Carcinogenesis, 2010
View PDFchevron_right
Overexpression of Bcl-xs Sensitizes MCF-7 Cells to Chemotherapy-induced Apoptosis1
Venil N Sumantran
View PDFchevron_right
Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
Jamie Beaumont
British Journal of Cancer
View PDFchevron_right
The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents in vitro and in vivo
Bernard Liu
Molecular Cancer …, 2011
View PDFchevron_right
Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer
Anton-Scott Goustin
Recent patents on anti-cancer drug discovery, 2008
View PDFchevron_right
Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells
David Mendiola Reynoso
Molecular Oncology, 2010
View PDFchevron_right
Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives
Mohamed Rahmani
Cancers, 2021
View PDFchevron_right